NadirAlphaNA EN · DE · ES · FR · 中文 · PL

Doximity Stock DOCS

Doximity, Inc. · SEC filings · Reporting currency USD · Quarterly reporting · Figures as of Q1 FY2027 (Apr to Jun 2026) · updated 2026-10-27 · ISIN US26622P1075

Doximity operates the largest professional network for U.S. Doximity stock (DOCS): Quarterly and annual results since 2024 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Doximity stock (DOCS): listed on NYSE. NadirAlpha has evaluated 36 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Revenue Q1 FY2027 (Apr to Jun 2026): USD 157 million (+7% year on year). Latest reported (Q1 FY2027 (Apr to Jun 2026)): Net revenue retention rate, Workflow active prescriber growth, Registered members. Latest reading: Net income halved, Revenue accelerating, Margin compressing, Guidance raised.

Net income halved Revenue accelerating Margin compressing Guidance raised

NadirAlpha editorial team · About us · Methodology

The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Doximity Current Status

Summary of the most recent reporting period of Doximity (Q1 FY2027): core figures, drivers and management statements, every figure with a source number. NadirAlpha methodology

Assessment by NadirAlpha, as of Q1 FY2027 (Apr to Jun 2026).

Doximity reported first-quarter fiscal 2027 revenue of 156.6 million, up 7% year-over-year, primarily driven by an $8.4 million increase in subscription revenue from new and expanded customers 29 30. Net income for the quarter was 24.3 million, with net margin compressing to 15.5% from 36.5% in the prior-year period 30. Adjusted EBITDA decreased 6% year-over-year to $74.8 million, with the adjusted EBITDA margin declining to 47.7% from 54.7% 30. Doximity raised its full-year FY2027 guidance to revenue of $671-681 million and adjusted EBITDA of $309-329 million, and the company's clinical AI assistant Doximity Ask was ranked as the top-performing U.S.-based model in the NOHARM benchmark 30.
Management commentary on the 2027-Q1 results (8-K-EX99.1, 2026-08-06):

“We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Jeff Tangney, co-founder and CEO 30
Revenue · 2027-Q1157$ million+7.3 % vs. 2026-Q1
Net profit · 2027-Q124$ million−54.4 % vs. 2026-Q1
EPS · 2027-Q10.13$−51.9 % vs. 2026-Q1
Revenue trend
Guidance
For FY2027, Doximity guides Revenue 671 to 681 $ million (raised); EBITDA (adjusted) 309 to 329 $ million (raised). 30 For 2027-Q2, Doximity guides Revenue 170 to 171 $ million (initiated); EBITDA (adjusted) 80.5 to 81.5 $ million (initiated). 30
Profitability
Doximity posted operating income of 33.6 million and net income of 24.3 million in the first quarter of fiscal 2027, with diluted earnings per share of 0.13 29. Net margin compressed to 15.5% from 36.5% in the prior-year period, and adjusted EBITDA margin declined to 47.7% from 54.7% on adjusted EBITDA of $74.8 million 30. Free cash flow for the quarter was 41.9 million 29.
Leverage
Doximity ended the first quarter of fiscal 2027 with a cash balance of 273.6 million, compared to 219.2 million at the end of the prior quarter. During the period, the company repurchased 4.76 million shares for $99.1 million under its February 2026 authorization, with $400.9 million remaining under the program 29. No net debt figure was disclosed, and the company maintained a net cash position at quarter end.
Recurring
Doximity's revenue growth in the first quarter of fiscal 2027 was primarily driven by an $8.4 million increase in subscription revenue from new and expanded customers 29. Subscriptions represent the company's core recurring revenue stream, underpinning total quarterly revenue of 156.6 million, an increase of $10.7 million compared to the prior-year period 29.
Management view
Doximity raised its full-year FY2027 outlook, guiding to revenue of $671-681 million and adjusted EBITDA of $309-329 million 30. Quarterly unique active providers using Workflow Tools grew approximately 32% year-over-year, reflecting increased adoption of the company's AI clinical tools 29. Doximity Ask, the company's clinical AI assistant, was ranked as the top-performing U.S.-based model in the NOHARM benchmark for clinical AI evaluation 30.
Change
Gross margin decreased 4 percentage points to 85% in the quarter, driven by higher hosting and software costs in support of AI initiatives 29. Research and development expense increased $11.7 million, primarily attributable to $9.6 million in stock-based compensation and new hires 29. Operating cash flow was 42 million, a decrease of 32% year-over-year 30.
Risks (current)
Doximity faces substantial and ongoing software and hosting costs for generative AI platform usage and inference supporting AI initiatives, representing a significant technology cost risk 29. Doximity is subject to pending securities class action and derivative litigation with a $31 million settlement subject to court approval, and as a HIPAA Business Associate it faces significant civil and criminal penalties for any compliance failures 28. Technology and content provider agreements are typically non-exclusive and easily terminable, and 83% of revenue is concentrated among customers with at least $500,000 in trailing twelve-month subscription revenue, creating customer concentration exposure 28.
New this reporting period
Doximity made contingent consideration payments related to its prior acquisition of AMiON during the first quarter of fiscal 2027, as disclosed in the quarterly filing 29. No new acquisitions or discrete product launches dated to this quarter were reported.

Doximity Stock: Key Figures ($ million)

The core financial figures of Doximity stock in three views: fiscal years up to FY2027, half-years and quarters up to Q1 FY2027, in $ million, most recent period first. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Revenue ($ million) · annual basis, as reported
Net income ($ million) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($ million) · annual basis, as reported
Revenue ($ million) · quarterly basis, as reported
Net income ($ million) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($ million) · quarterly basis, as reported
Cash ($ million) · annual basis, as reported
Capex ($ million) · annual basis, as reported
FCF ($ million) · annual basis, as reported
D&A ($ million) · annual basis, as reported
Cash ($ million) · quarterly basis, as reported
Capex ($ million) · quarterly basis, as reported
FCF ($ million) · quarterly basis, as reported
D&A ($ million) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2021 is on record.

Fiscal years

Amounts in $ million · EPS in $ per share · as reported
Doximity stock: key figures on annual basis, FY2024 to FY2026, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodCalendar quarterRevenueOp. incomeOp. income (adj.)Net incomeEPS ($)EPS adj. ($)EBITDA (adj.)OCFSource
FY2026Q2/2025–Q1/2026644.9214.9349.9196.10.981.52357.82326.527
FY2025Q2/2024–Q1/2025570.4227.8307.4223.21.111.420.31273.319
FY2024Q2/2023–Q1/2024475.4163.9224.8147.60.720.95230.46184.112

Quarters

Amounts in $ million · EPS in $ per share · as reported
Doximity stock: key figures on quarterly basis, 2024-Q1 to 2027-Q1, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodCalendar quarterPublishedRevenueOp. incomeOp. income (adj.)Net incomeEPS ($)EPS adj. ($)EBITDA (adj.)FCFCashSource
2027-Q1*Q2/20262026-08-06156.633.6–24.30.130.29°74.841.9273.629
2026-Q4*Q1/20262026-05-13145.424.863.619.10.10*≈0.25≈65.8–219.2127
2026-Q3*Q4/20252026-02-05185.171.9109.361.60.310.46111.4–64.8126
2026-Q2*Q3/20252025-11-06168.563.79962.10.310.45100.8–169.2124
2026-Q1*Q2/20252025-08-07145.954.57853.30.270.3679.862.1137.321
2025-Q4*Q1/20252025-05-15138.348.76862.50.31*≈0.39≈69.798.5209.619
2025-Q3*Q4/20242025-02-06168.679.9100.475.20.370.4510265.2165.317
2025-Q2*Q3/20242024-11-07136.853.174.644.20.220.3076.168.3184.215
2025-Q1*Q2/20242024-08-08126.746.164.441.40.210.2865.941.2111.413
2024-Q4*Q1/20242024-05-16118.141.95540.60.20*≈0.25≈56.563.996.811
2024-Q3*Q4/20232024-02-08135.358.671.8480.240.2973.350123.19
2024-Q2*Q3/20232023-11-09113.633.852.830.60.150.2254.212.9108.47
2024-Q1*Q2/20232023-08-08108.529.745.228.40.130.1946.657.1306.75
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Net Debt (not reported in any source for these periods).

Doximity Balance Sheet & Cash Flow ($ million)

Point-in-time balance sheet items of Doximity (cash, financial debt) and cash flow items per fiscal year, half-year and quarter, derived values with their formula in the popover. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

Fiscal years

Amounts in $ million · as reported
Doximity stock: balance sheet and cash flow on annual basis, FY2024 to FY2026, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodCalendar quarterPublishedCashD&AOCFCapexFCFSource
FY2026Q2/2025–Q1/20262026-05-13219.214.4326.50326.527
FY2025Q2/2024–Q1/20252025-05-15209.610.7273.30273.319
FY2024Q2/2023–Q1/20242024-05-1696.810.3184.10.1183.911

Quarters

Amounts in $ million · as reported
Doximity stock: balance sheet and cash flow on quarterly basis, 2024-Q1 to 2027-Q1, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodCalendar quarterPublishedCashD&AOCFCapexFCFSource
2027-Q1Q2/20262026-08-06273.64.3420.141.929
2026-Q4Q1/20262026-05-13219.24.1109.5––127
2026-Q3Q4/20252026-02-0564.8460.9––126
2026-Q2Q3/20252025-11-06169.23.593.9––124
2026-Q1Q2/20252025-08-07137.32.862.1062.121
2025-Q4Q1/20252025-05-15209.62.898.5098.519
2025-Q3Q4/20242025-02-06165.32.765.2065.217
2025-Q2Q3/20242024-11-07184.22.668.3068.315
2025-Q1Q2/20242024-08-08111.42.641.2041.213
2024-Q4Q1/20242024-05-1696.82.563.9063.911
2024-Q3Q4/20232024-02-08123.12.550.10509
2024-Q2Q3/20232023-11-09108.42.612.9012.97
2024-Q1Q2/20232023-08-08306.72.657.20.157.15
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Doximity Guidance Tracking (latest per metric/period · 10/22)

NadirAlpha records 22 guidance statements of Doximity neutrally: annual and quarterly targets, direction of change and outcome as a dot with legend, with no estimate of our own. NadirAlpha methodology

Actuals: revenue in $m

Direction: confirmedinitiatedraised Verdict: beatpending

Doximity: guidance and actuals per metric and period, 22 entries. Compiled by NadirAlpha from SEC filings.
For periodGuided onMetricGuidedActualVerdictDirectionSource
FY20272026-08-06Revenue671–681–30
FY20272026-08-06EBITDA (adjusted)309–329–30
2027-Q22026-08-06Revenue170–171–30
2027-Q22026-08-06EBITDA (adjusted)80.5–81.5–30
FY20262026-02-05Revenue642.5–643.5644.926
FY20262026-02-05EBITDA (adjusted)355.5–356.5357.8226
2026-Q42026-02-05Revenue143–144145.426
2026-Q42026-02-05EBITDA (adjusted)63.5–64.565.826
2026-Q22025-08-07Revenue157–158168.522
2026-Q22025-08-07EBITDA (adjusted)87–88100.822
FY20252024-11-07Revenue535–540570.416
FY20252024-11-07EBITDA (adjusted)274–2790.3116
2025-Q32024-11-07Revenue152–153168.616
2025-Q32024-11-07EBITDA (adjusted)83–8410216
2025-Q22024-08-08Revenue126.5–127.5136.814
2025-Q22024-08-08EBITDA (adjusted)62.5–63.576.114
FY20242024-02-08Revenue473.3–474.3475.410
FY20242024-02-08EBITDA (adjusted)224.5–225.5230.4610
2024-Q42024-02-08Revenue115.9–116.9118.110
2024-Q42024-02-08EBITDA (adjusted)50.5–51.556.510
2024-Q22023-08-08Revenue108.5–109.5113.66
2024-Q22023-08-08EBITDA (adjusted)44–4554.26

Doximity Stock: Price & Chart

Chart and key figure trend of Doximity stock: the TradingView chart starts only on click, the key figure chart comes from the core tables up to Q1 FY2027. NadirAlpha methodology

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Doximity Event Timeline

What happened at Doximity since 2024: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology

Overview: one dot per event · click jumps to the period
earningsrevenuemarginguidancestrategyfinancials2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q42027-Q1
2027 · 4 events

Revenue accelerating 2026-08-06
Revenue rose 7% year-over-year to 156.6 million, led by an $8.4 million increase in subscription revenue from new and expanded customers 29 30
Margin compressing 2026-08-06
Gross margin decreased 4 percentage points to 85%, driven by higher hosting and software costs supporting AI initiatives 29
Guidance raised 2026-08-06
Doximity raised FY2027 revenue guidance to $671 to 681 million and adjusted EBITDA guidance to $309 to 329 million 30
Net income halved 2026-08-06
Net income more than halved YoY (53.3 to USD 24.3 million, -54%). 29
2026 · 11 events

“We're thrilled to announce that we reached a new engagement record of over 800,000 active prescribers using our workflow tools in Q4. Nearly half of those providers used our clinical AI last quarter, while our prompts per user nearly doubled from January to April alone. Our new partnerships with Aledade and Photon build on that momentum, bringing our Clinical AI Suite to thousands of independent practices and enabling seamless in-workflow prescribing for the first time. I'm also thrilled to welcome Matt Sonefeldt as our new CFO and Dr. Steve Zatz as our new President, two exceptional leaders whose experience and relationships will be instrumental as we continue to scale.”

Jeff Tangney, co-founder and CEO 27
Strategic pivot 2026-05-13
Matt Sonefeldt appointed as new CFO and Dr. Steve Zatz appointed as new President 27
Partnership 2026-05-13
New partnerships with Aledade and Photon expand the Clinical AI Suite to independent practices with in-workflow prescribing 27
Net income halved 2026-05-13
Net income more than halved YoY (62.5 to USD 19.1 million, -69%). 127

“We're proud to deliver another quarter of strong profits and record engagement. Our newsfeed had more than 1 million quarterly active prescribers, our workflow products had 720,000 (a record QoQ jump), and our nascent AI products had over 300,000. In short, the addition of AI features across our platform has made us more useful than ever.”

Jeff Tangney, co-founder and CEO 26
revenue 2026-02-05
Revenue growth slowed to 10% year-over-year to 185.1 million 26
Regulation 2026-02-05
Settlement reached on December 24, 2025 for securities class action litigation; Doximity to pay $31 million covered by insurance 25
Revenue decelerating 2026-02-05
Revenue growth decelerated to +9.8% YoY (prior period +23.2%). 126

“Our platform continues to grow with new AI tools to save physicians' time. In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarter.”

Jeff Tangney, co-founder and CEO 24
Revenue accelerating 2025-11-06
Revenue growth accelerated to 23% year-over-year, reaching 168.5 million 23
Margin expanding 2025-11-06
Adjusted EBITDA margin improved to 60% for the three-month period, up from 56% in the prior year quarter 23

“We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products. Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients.”

Jeff Tangney, co-founder and CEO 22
revenue 2025-08-07
Revenue grew 15% year-over-year to 145.9 million, below the 20% full-year growth rate of FY2025 21 28
Margin expanding 2025-08-07
Adjusted EBITDA margin expanded to 55% from 52% in the prior year quarter 21
Acquisition 2025-08-07
Doximity acquired Pathway Medical 22
2025 · 13 events

“We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth. Our newsfeed, workflow, and AI tools all hit fresh highs in Q4, helping doctors save time and provide the best care for their patients.”

Jeff Tangney, co-founder and CEO 19
earnings 2025-05-15
FY2025 net income up 51% to USD 223.2 million; Q4 net income USD 62.5 million with margin of 45.2% vs 34.4% prior year 19
revenue 2025-05-15
Q4 revenue up 17% YoY to USD 138.3 million; FY2025 total revenues up 20% to USD 570.4 million with subscription revenue up 21% to $543.8M 19
Guidance initiated 2025-05-15
FY2026 guidance initiated: revenue $619M-$631M and adjusted EBITDA $333M-$345M; Q1 FY2026 revenue $139M-$140M, adjusted EBITDA $71M-$72M 19

“We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools. Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers.”

Jeff Tangney, co-founder and CEO 18
earnings 2025-02-06
Net income up 57% to USD 75.2 million; adjusted EBITDA grew 39% YoY 17 18
Revenue accelerating 2025-02-06
Revenue up 25% YoY to USD 168.6 million driven by $32.8M subscription revenue increase from existing customer expansion 17
Margin expanding 2025-02-06
Adjusted EBITDA margin expanded to 60.5% from 54.2% YoY; gross margin improved to 92% from 91% 18 17

“Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers. We're proud to help physicians save time, so they can provide better care for their patients.”

Jeff Tangney, co-founder and CEO 16
earnings 2024-11-07
Adjusted EBITDA increased 41% to $76.1M; adjusted EBITDA margin expanded to 56% from 48% YoY 15 16
Revenue accelerating 2024-11-07
Revenue up 20% YoY to USD 136.8 million driven by $23.0M subscription revenue increase from new and expanded customers 15
Margin expanding 2024-11-07
Gross margin expanded to 90% in Q2 from 89% in prior year; H1 gross margin 90% vs 88% prior year 15
Cash flow inflection 2024-11-07
Operating cash flow reached USD 68.3 million vs USD 12.9 million in 2024-Q2 (×5.3). 124

“We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines. Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save time and better serve their patients.”

Jeff Tangney, co-founder and CEO 14
earnings 2024-08-08
Net income up 46% to USD 41.4 million; adjusted EBITDA up 42% YoY 14
Revenue accelerating 2024-08-08
Revenue up 17% YoY to USD 126.7 million driven by $18.7M subscription revenue increase from new and expanded customers 13
Margin expanding 2024-08-08
Adjusted EBITDA margin expanded to 52% from 43% YoY; non-GAAP net income margin improved to 44.1% from 37.5% 14
2024 · 14 events

“We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement. We're proud to bring AI and automation to clinical workflows, with over 580,000 unique providers using our workflow tools last quarter.”

Jeff Tangney, co-founder and CEO 11
New market 2024-05-23
Doximity launched Doximity GPT, a HIPAA-compliant generative AI writing assistant for physicians and medical professionals 12
revenue 2024-05-16
Q4 revenue up 6% year-over-year to USD 118.1 million; full-year revenue USD 475.4 million, up 13% year-over-year 11
Strategic pivot 2024-05-16
$500 million share repurchase program authorized on May 1, 2024 11
Revenue decelerating 2024-05-16
Revenue growth decelerated to +6.4% YoY (prior period +17.3%). 119

“We're proud to deliver another quarter of double-digit engagement growth across our entire platform, with a beat and raise on both our top and bottom lines. Our clinical workflow tools continue to drive daily use among doctors, and we now count 17 of the top 22 U.S. hospitals as enterprise software clients.”

Jeff Tangney, co-founder and CEO 10
Revenue accelerating 2024-02-08
Revenue up 17% year-over-year to USD 135.3 million, re-accelerating from Q2's 11% growth rate 9
Margin expanding 2024-02-08
Adjusted EBITDA margin improved to 54% from 48% in the prior-year quarter 9
Guidance raised 2024-02-08
FY2024 revenue guidance raised to $473.3-474.3 million and adjusted EBITDA guidance to $224.5-225.5 million 10

“We're proud to make medicine mobile, with another quarter of record engagement across our entire platform. Over 550,000 unique providers used our generative AI, telehealth, messaging, and scheduling workflow tools in Q2 to provide better care for their patients.”

Jeff Tangney, co-founder and CEO 8
revenue 2023-11-09
Revenue grew 11% year-over-year to USD 113.6 million, slowing from the prior quarter's 20% growth rate 8
Margin expanding 2023-11-09
Adjusted EBITDA margin reached 47.7%, up year-over-year, as adjusted EBITDA rose 18% to $54.2 million 8

“We're pleased to report another quarter of record engagement across our entire platform, with over 525,000 unique providers using our workflow tools in Q1. Looking ahead, we are focused on streamlining our client workflows, so we can fully capitalize on our long-term potential.”

Jeff Tangney, co-founder and CEO 6
Revenue accelerating 2023-08-08
Revenue up 20% year-over-year to USD 108.5 million, driven by $17.5 million subscription revenue growth including $4.7 million from new customers and $12.8 million from expansion 5
Guidance raised 2023-08-08
FY2024 revenue guidance raised to $452-468 million and adjusted EBITDA guidance raised to $193-209 million 6
Strategic pivot 2023-08-08
Workforce reduction of approximately 100 employees, representing 10% of workforce, announced 6
Margin compressing 2023-05-26
Gross margin declined 1 percentage point to 87%, attributed to headcount growth and U.S. News partnership expenses 4
revenue 2023-05-26
Full-year revenue USD 419.1 million grew 22% year-over-year, compared to 66% growth in fiscal year 2022 4

Doximity Business Model

The Doximity business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology

Doximity operates the largest professional network for U.S. physicians and healthcare professionals, providing workflow software tools that include secure clinical messaging, telehealth features, a medical career directory, and drug reference resources. Doximity earns revenue primarily through annual subscription agreements with hospitals, health systems, pharmaceutical companies, and medical device manufacturers, who pay for access to the platform's verified physician network and targeted engagement capabilities. Subscription fees represent the dominant revenue stream, structured as enterprise contracts that scale with deployment scope and the modules activated. The platform's verified membership base and resulting data network create recurring enterprise relationships, with a significant portion of revenue derived from a concentrated group of large-spending healthcare enterprise customers.

Doximity Stock: Share-Price Drivers

What determines the business trajectory of Doximity according to management, summarised from the reports up to Q1 FY2027. NadirAlpha methodology

Adoption of Doximity's Clinical AI Suite across U.S. health systems
Doximity reports its Clinical AI Suite has been taken up by 140+ U.S. health systems, deepening clinician engagement that underpins its pharma and hiring monetisation 28
Clinical AI product traction (Clinical AI Suite, Scribe, Ask/PeerCheck)
Doximity has launched a Clinical AI Suite adopted by 140+ U.S. health systems, together with the Scribe ambient documentation tool, the Ask (formerly DoxGPT) assistant and a PeerCheck verification layer, pointing to broadening uptake of its AI tools 28
Telehealth Dialer with enterprise option
Doximity offers a Dialer telehealth solution with an enterprise option, extending the workflow tools available to clinicians 28
Acquisitions adding clinical capabilities and staffing reach
Doximity completed the Pathway Medical acquisition in July 2025 and continues to operate the Curative Talent physician staffing business, broadening its product and hiring footprint 28
Scheduling and hiring tools (AMiON, Curative Talent)
Doximity runs the AMiON on-call scheduling tool and the Curative Talent staffing firm, supporting the hiring and workflow modules that sit alongside its core network 28
Revenue and cash generation trajectory
Doximity posted revenue of 156.6 million with operating income of 33.6 million and free cash flow of 41.9 million in 2027-Q1, with cash of 273.6 million; guidance was raised 28
Capital return via share repurchases
Doximity has an authorised stock repurchase program that continues to return capital to shareholders 25

Sector trend: Demand in the digital health and healthcare IT sector is tilting toward AI-enabled clinical workflow tools, with Doximity's Clinical AI Suite reaching 140+ U.S. health systems indicating rising clinician adoption of ambient documentation and reference tools 28. The company's product mix of networking, hiring and telehealth modules points to steady utilisation of clinician engagement rather than a narrow single-product dependency 28.

Doximity Products & announcements (10/17 active+recent)

17 product announcements of Doximity since 2024, grouped by year; active means still mentioned in the most recent reports, nothing is deleted. NadirAlpha methodology

Status: PlannedLaunched

Doximity: product announcements from the filings, 17 entries. Compiled by NadirAlpha from SEC filings.
Product/LineSinceStatusSource
2026
AI-powered clinical reference and search capabilities launch2026-0926
Scribe ambient AI documentation tool for clinical notes202628
Scribe HIPAA-compliant ambient note taking tool202628
PeerCheck AI feature202628
Clinical AI Suite adoption by 140+ U.S. health systems202628
Clinical AI Suite202628
Ask (formerly DoxGPT) with PeerCheck physician verification layer202628
Ask (formerly DoxGPT)202628
2025
Dialer Enterprise telehealth solution launch (2x)202528
2024
AMiON on-call scheduling tool202428
2025
Doximity GPT launch202520
Doctor Finder collaboration with U.S. News & World Report202520
2024
Residency Navigator tool202420
Doximity GPT AI writing assistant202412
Dialer telehealth product202412
2023
Telehealth platform2023-092
Workforce reduction plan2023-086

Doximity Transactions & Events (6)

Transactions of Doximity since 2024: acquisitions, disposals, agreements and regulation, deliberately including smaller items; purchase prices only when the company names them. NadirAlpha methodology

Acquisitions · 3Partnerships/contracts · 1older: 2 (in the table)
20252026

Acquisitions by Doximity

Doximity: Acquisitions, 5 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2025
Pathway Medical Acquisition2025-07Completed28
AMiON acquisition contingent consideration payments2025-03Completed29
2024
Curative Talent physician staffing firm2024Completed12
2022
AMiON acquisition2022-04Completed28
2021
Curative Talent acquisition2021Completed28

Partnerships and contracts of Doximity

Doximity: Partnerships & contracts, 1 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2026
Partnership with Photon (2x)2026Agreement27

Doximity Risks (96 since the annual report of 2026-05-19, 275 tracked in total)

Which risks Doximity has named since the annual report, company-specific first, generic standard risks in the expandable part; first mention refers to the document base from 2023. NadirAlpha methodology

Category: TechnologyMacroLegalFinancialCyberCustomersPeopleRegulatoryStrategyESGMarketCompetitiongeschaeft

Doximity: risk factors as reported, 96 since the last annual report, 275 tracked. Compiled by NadirAlpha from SEC filings.
RiskCategoryLast reported
Doximity: first mention in 10-Q quarterly report of 2026-08-06 (2027-Q1), source 29
Substantial ongoing software and hosting costs for generative AI platform usage and inference supporting AI initiatives.=
Doximity: first mention in 10-Q quarterly report of 2023-08-08 (2024-Q1), source 5
Unable to fully offset inflationary cost pressures could harm business and financial condition.2027-Q1
2026-08-06 29
Doximity: first mention in 10-K annual report of 2023-05-26 (FY2023), source 4
Shareholder class action litigation addressed in non-GAAP reconciliation; legal fees material to adjusted EBITDA.2027-Q1
2026-08-06 29
Hypothetical 100 basis point rate increase would decrease investment values by $2.6-3.4 million.2027-Q1
2026-08-06 29
Doximity: first mention in 10-K annual report of 2026-05-19 (FY2026), source 28
Platform stores sensitive information including protected health information; security breaches could result in data loss, litigation, regulatory actions, and reputational damage.=
May be liable for privacy and security failures of subcontractors and vendors under HITECH and other data protection requirements.=
Depend on limited customers and marketing agencies for significant revenue portion=
Pharmaceutical customers do not typically enter long-term contracts and can terminate relationships=
Former Chief Financial Officer departed April 2026; Chief Accounting Officer served as interim CFO during search; Matt Sonefeldt appointed CFO May 13, 2026.=
Member-first decisions may forgo revenue opportunities and harm financial results=
Dual-class stock structure concentrates voting power with Class B holders limiting minority shareholder influence=
Numerous pending laws relating to use of AI in healthcare could impact physician platform engagement=
Complex state fee-splitting laws and corporate practice of medicine restrictions may require business model changes=
Relies on Amazon Web Services for computing and storage; Google for storage and collaboration tools; service unavailability could increase expenses and impair operations.=
Increasing focus on ESG matters; failure to achieve ESG commitments could result in criticism and reputational harm.=
Changes in accounting rules, assumptions, or judgments could materially impact financial statements or require restatement.=
Volatility in capital markets may affect ability to access capital through equity or debt financing; economic downturns could limit financing availability.=
Events affecting financial institutions or counterparties could lead to liquidity problems and impair ability to access funds.=
Incorrect estimates or judgments relating to critical accounting policies could adversely affect results of operations.=
Debt financing could involve restrictive covenants limiting capital raising and business opportunities.=
Future equity issuances could cause significant dilution to existing stockholders.=
Contractual limitations on liability may not be enforceable or provide sufficient protection; insurance coverage may be inadequate.=
Subject to changes in tax laws, regulations, and administrative practices which could materially affect effective tax rate.=
Disaster recovery program allows traffic movement to backup data center but may not effectively support timely or complete traffic movement.=
General economic conditions including inflation and interest rates may adversely impact discretionary customer spending=
Pandemic, epidemic, or infectious disease could disrupt operations, reduce customer spending, and impair business growth.=
Federal pricing initiatives and policy changes affect pharmaceutical customer marketing spend decisions=
Ability to increase sales to new customers and expand to existing customers; customer renewals and terminations; competitor entry; pricing changes.=
Rapid growth and organizational change strain management and operational infrastructure=
Laws of foreign countries may not protect intellectual property rights to same extent as U.S. laws; enforcement in foreign jurisdictions costly and difficult.=
Enforcement of intellectual property rights is expensive and time-consuming; courts may refuse to enforce rights or find rights invalid or unenforceable.=
Protection of domain names, trademarks, patents, and trade secrets is expensive; efforts may not prevent misappropriation or misuse.=
Solutions include open source software; failure to comply with open source licenses could require release of proprietary source code or re-engineering.=
No issued patents obtained; pending patent applications may not result in issued patents; issued patents may not provide competitive advantage.=
Failure to comply with third-party license agreements could result in damages and loss of critical license rights.=
HIPAA compliance requirements and healthcare data processing obligations may increase operational costs=
Acquisitions may involve unanticipated costs, margin impacts, management distraction, and increased legal and accounting compliance costs.=
Data providers could withdraw data or restrict usage for competitive or legislative reasons; loss of data providers could materially impact solutions.=
Growth initiatives and operating plans may not achieve expected benefits; implementation may be more costly or time-consuming than anticipated.=
Increasing dependence on third-party distribution of mobile applications through app stores and super-app environments.=
Collaborations, in-licensing arrangements, joint ventures, and strategic alliances may not result in commercially viable solutions or significant revenue.=
Licenses for third-party software and components may not be available on commercially reasonable terms or could be terminated.=
AI systems may produce inaccurate, incomplete, biased, or misleading outputs including hallucinations reflecting errors or training data bias.=
AI and ML present ethical issues; controversy about impact on society could result in brand harm, reputational harm, or legal liability.=
AI development may not achieve expected benefits and creates operational and reputational risks=
AI-enabled offerings may not perform as expected, may not be adopted, or may fail to improve competitive position.=
AI-enabled tools may generate materials alleged to infringe third-party intellectual property or privacy rights.=
AI-enabled tools susceptible to prompt injection, data poisoning, model manipulation, malicious inputs, and unauthorized access to models or training data.=
Reliance on third-party infrastructure including Amazon Web Services creates dependencies=
Must continuously improve and upgrade systems and infrastructure while maintaining reliability; failure could impair competitiveness.=
Success depends on interoperability with third-party technologies, systems, networks, operating systems; loss of interoperability could materially affect growth.=
Undetected errors or design faults could adversely affect business and financial condition=
Integration of third-party AI models, platforms, vendors may be inadequate; third parties may change terms, pricing, or data-use practices adversely.=
Compete with healthcare staffing companies and job boards for recruiting budgets=
Larger technology companies (LinkedIn, Facebook, Google, X) compete for members=
Compete with WebMD Medscape and OpenEvidence for pharmaceutical marketing budgets=
Compete with Zoom, Teams, Teladoc, American Well, QGenda, Abridge, OpenAI=
Healthcare industry consolidation may increase customer negotiating power and reduce demand=
Doximity: first mention in 10-Q quarterly report of 2025-11-06 (2026-Q2), source 23
OpenEvidence patent infringement suit ongoing in Massachusetts federal court with uncertain outcomeFY2026
2026-05-19 28
Five shareholder derivative lawsuits pending relating to breach of fiduciary duties and mismanagement=
Significant portion of acquisition purchase prices allocated to goodwill and intangible assets; if acquisitions underperform, impairment charges could harm results.FY2026
2026-05-19 28
Doximity: first mention in 10-K annual report of 2025-05-20 (FY2025), source 20
Subject to litigation; claims may result in significant defense costs, judgments, settlements, and damage to reputation and customer relationships.FY2026
2026-05-19 28
General industry and macroeconomic conditions could adversely impact sales.FY2026
2026-05-19 28
Global economic downturn could reduce pharmaceutical and health system spendingFY2026
2026-05-19 28
Subject to claims alleging intellectual property infringement; defending claims could be costly and divert management resources.FY2026
2026-05-19 28
Current protections from third-party content liability under Section 230 of CDA could decrease or change due to proposed amendments.FY2026
2026-05-19 28
Healthcare law changes including telehealth parity and HIPAA enforcement resumption after COVID-19 restrictions liftFY2026
2026-05-19 28
Internally calculated operational metrics lack independent third-party verificationFY2026
2026-05-19 28
Doximity: first mention in 10-K annual report of 2024-05-23 (FY2024), source 12
Accumulated 3.7 million of state NOLs; ability to use may be limited under Section 382 and 383 if ownership change occurs.FY2026
2026-05-19 28
Subject to state laws restricting business relationships between entities and physiciansFY2026
2026-05-19 28
Subject to stringent, evolving privacy, data protection, and information security laws; failure to comply could result in fines, liability, and reputational harm.FY2026
2026-05-19 28
Substantial portion of workforce working remotely increases cybersecurity risk and data accessibility concerns.FY2026
2026-05-19 28
Equity incentive plans and future capital raises may dilute existing shareholder ownership percentagesFY2026
2026-05-19 28
Decrease in member retention could render platform less attractive to customersFY2026
2026-05-19 28
Evolving laws governing AI development and use may increase compliance costs and require business practice changes.FY2026
2026-05-19 28
Must comply with state medical privacy laws more protective than HIPAA and comprehensive state privacy legislation like CCPA and CPRA.FY2026
2026-05-19 28
Significant interruptions or delays in service or undetected errors could adversely affect business, financial condition, and results of operations.FY2026
2026-05-19 28
Doximity: first mention in 10-K annual report of 2023-05-26 (FY2023), source 4
Members use platform for communications subject to TCPA and other laws; noncompliance could result in fines, penalties, and private rights of action.FY2026
2026-05-19 28
Subject to U.S. federal and state income taxes; enactment of One Big Beautiful Bill Act (July 4, 2025) and Inflation Reduction Act changes tax obligations.FY2026
2026-05-19 28
Securities and derivative lawsuits filed; settlement agreed for securities class action.2026-Q3
2026-02-05 25
Historical revenue growth of 13% in FY2026 vs 20% in FY2025 may not be sustainableFY2026
2026-05-19 28
Risk management policies and procedures may not be fully effective in identifying and mitigating all business risks.FY2026
2026-05-19 28
Natural disasters, power disruptions, terrorism, or other catastrophic events could disrupt operations, cause data loss, and impair business continuity.FY2026
2026-05-19 28
Doximity: first mention in 10-Q quarterly report of 2023-02-09 (2023-Q3), source 1
83% of revenue from customers with at least $500k trailing twelve-month subscription revenueFY2026
2026-05-19 28
Loss of senior management or key employees, particularly CEO, could materially adversely affect business execution and growth.FY2026
2026-05-19 28
Securities class action and derivative litigation pending with $31M settlement subject to court approvalFY2026
2026-05-19 28
As HIPAA Business Associate, faces significant penalties for compliance failures including civil, criminal penalties, and imprisonment.FY2026
2026-05-19 28
Completed acquisitions of Curative Talent (fiscal 2021), AMiON (fiscal 2023), and Pathway Medical (July 2025); future acquisitions may fail to integrate or yield expected returns.FY2026
2026-05-19 28
Agreements with technology and content providers typically non-exclusive and easily terminable; third parties may underperform or terminate relationships.FY2026
2026-05-19 28
Failure to implement and maintain effective internal controls over financial reporting could harm investor confidence and stock price.FY2026
2026-05-19 28
Any factor diminishing reputation could make difficult to attract customers and membersFY2026
2026-05-19 28
Platform allows content exchange exposing company to claims for defamation, misinformation, discrimination, harassment, and intellectual property violations.FY2026
2026-05-19 28
Trade secrets difficult to protect; reliance on confidentiality agreements which may be breached or inadequate; competitors may independently develop similar technology.FY2026
2026-05-19 28
Trademarks may be challenged, infringed, declared generic, or determined to be infringing on other marks; inability to protect brand could harm business.FY2026
2026-05-19 28
Significant legal, accounting, insurance, and compliance costs of being a public company; no longer emerging growth company increases expenses.FY2026
2026-05-19 28
Reliance on Apple App Store and Google Play for distribution creates risk to app availability and termsFY2026
2026-05-19 28
= last mention identical with the first mention (same source)

Doximity Reported KPIs (as disclosed) (96)

NadirAlpha collects 96 reported KPIs of Doximity from the filings up to Q1 FY2027; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
Doximity: reported KPIs as disclosed, 96 entries. Compiled by NadirAlpha from SEC filings.
KPIValue / changeSource
Doximity, published 2026-08-06, period 2027-Q1
Workflow active prescriber growthmore than 30%30
Registered membersover 3 million29
Quarterly unique active providers using Workflow Tools YoY growth32%29
Net revenue retention rate107%29
Customers with at least $500,000 TTM revenue12729
Cash, cash equivalents and marketable securities687.8 million29
AI Search query growthover 25%30
Doximity, published 2026-05-19, period FY2026
US physicians represented %more than 85%28
US nurse practitioners / physician assistants %two-thirds28
US medical students %approximately 90%28
Total US physiciansapproximately 1 million28
Registered trademarks US1528
Registered trademarks non-US428
Registered members US physicians %more than 85%28
Registered membersover 3 million28
Quarterly unique active providers using Workflow Tools0.8128
Pending patent applications US1428
Net revenue retention rate109%28
Granted patents US628
FTE R&D %more than a third28
Customers with at least $500k revenue12528
Doximity, published 2026-05-13, period FY2026
Quarterly unique active providers using workflow toolsover 800,00027
Providers using clinical AInearly half27
Doximity, published 2026-02-05, period 2026-Q3
Net revenue retention rate112%25
Customers with at least $500k TTM revenue12625
Workflow products active users720,00026
Newsfeed quarterly active prescribersmore than 1 million26
AI products active usersover 300,00026
Doximity, published 2025-11-06, period 2026-Q2
Prescribers using workflow tools650,00024
Net revenue retention rate prior year116%23
Net revenue retention rate118%23
Customers with at least $500k TTM subscription revenue prior year10423
Customers with at least $500k TTM subscription revenue12123
AI Scribe and DoxGPT user growth from prior quarterover 50%24
Doximity, published 2025-08-07, period 2026-Q1
Net revenue retention rate118%21
Customers with at least $500,000 of revenue12021
Doximity, published 2025-05-20, period FY2025
US physicians penetrationover 80%20
US nurse practitioners / physician assistants penetrationover 60%20
US medical students penetrationover 90%20
Unique active providers clinical workflow toolsmore than 620,00020
Registered trademarks non-USfour20
Registered or applied trademarks USfifteen20
Registered membersover two million20
Pending patent applicationstwelve20
Net revenue retention rate119%20
Granted patentsfour20
Customers with at least $500k revenue11620
Doximity, published 2025-02-06, period 2025-Q3
Unique providers using clinical workflow toolsover 610,00018
Unique providers on newsfeedmore than one million18
Net revenue retention rate (prior year)115%17
Net revenue retention rate117%17
Customers with at least $500,000 of revenue (prior year)9417
Customers with at least $500,000 of revenue11417
AI tools growthup 60% over the prior quarter18
Doximity, published 2024-11-07, period 2025-Q2
Unique active prescribersover 600,00016
Net revenue retention rate116%15
Net income margin32%15
Customers with at least $500,000 of revenue10315
Adjusted EBITDA margin56%15
Doximity, published 2024-08-08, period 2025-Q1
Net revenue retention rate114%13
Customers with at least $500k revenue10213
Unique providers using AI, telehealth, messaging, and scheduling workflow tools590,00014
Doximity, published 2024-05-23, period FY2024
Unique active providers clinical workflow toolsmore than 580,00012
Registered trademarks non-USfour12
Registered or applied for trademarks USfifteen12
Registered membersover two million12
Physicians in USmore than 80%12
Pending international PCT applicationstwo12
Nurse practitioners physician assistantsover 60%12
Granted patents USone12
Graduating US medical studentsover 90%12
Net revenue retention rate114%12
Customers with at least $500,000 of revenue (FY2024)9812
Customers with at least $500,000 of revenue (FY2023)8012
Customers with at least $500,000 of revenue (FY2022)7112
Customers with at least $100,000 of revenue (FY2024)29612
Customers with at least $100,000 of revenue (FY2023)29412
Customers with at least $100,000 of revenue (FY2022)25112
Doximity, published 2024-05-16, period 2024-Q4
Subscription revenue (prior year)103.2 million11
Subscription revenue (full year)450.1 million11
Subscription revenue (full year prior)389.7 million11
Subscription revenue112.7 million11
Operating cash flow (prior year)46.6 million11
Operating cash flow (full year)184.1 million11
Operating cash flow (full year prior)179.6 million11
Operating cash flow63.9 million11
Doximity, published 2024-02-08, period 2024-Q3
Net revenue retention rate115%9
Customers with $100k+ revenue2899
Doximity, published 2023-11-09, period 2024-Q2
Unique providers using generative AI, telehealth, messaging, and scheduling workflow tools550,0008
Customers with at least $100,000 revenue2907
Net revenue retention rate114%7
Net income margin25%7
Adjusted EBITDA margin41%7
Doximity, published 2023-08-08, period 2024-Q1
Net revenue retention rate118%5
Customers with TTM revenue >$100k2965
Unique providers using workflow tools525,0006

Doximity Development

How Doximity has developed since 2024: one paragraph per period on revenue, earnings, cash flow and drivers, most recent period first, grouped by year. NadirAlpha methodology

FY2027: Doximity

In fiscal first quarter 2027, Doximity generated revenue of 156.6 million, a 7% increase year-over-year driven primarily by an $8.4 million rise in subscription revenue from new and expanded customers 29. Gross margin contracted 4 percentage points to 85% as hosting and software costs rose to support AI initiatives, and adjusted EBITDA declined 6% to $74.8 million with adjusted EBITDA margin compressing to 47.7% from 54.7% in the prior-year period 29 30. Net income fell to 24.3 million, while operating cash flow declined to 42 million 30. Following the quarter, Doximity raised its full-year fiscal 2027 revenue guidance to $671 to 681 million and adjusted EBITDA guidance to $309 to 329 million 30. Quarterly unique active providers using Workflow Tools grew approximately 32% year-over-year, and the company's clinical AI assistant ranked as the top-performing U.S.-based model in the NOHARM benchmark 29 30.

FY2026: Doximity

Doximity reported fiscal year 2026 revenues of 644.9 million, up 13% year-over-year, driven by a $64.6 million increase in subscription revenue with $16.2 million from new customers and $48.4 million from expansion of existing customers 28. Net income declined to 196.1 million from $223.2 million in the prior year, primarily due to increased operating expenses in research and development, sales and marketing, and general and administrative functions, while adjusted EBITDA rose to $357.8 million, up 14% year-over-year 27 28. Operating cash flow reached 326.5 million, up 19% year-over-year, and free cash flow was 326.5 million, also up 19% year-over-year 27. Doximity expanded its platform through the acquisitions of Pathway Medical, Curative Talent, and AMiON, and the Clinical AI Suite was adopted by more than 140 leading U.S. health systems by fiscal year-end 28. Doximity completed its first $500 million share repurchase program and initiated a second $500 million program in February 2026, and reached a $31 million securities class action settlement covered by insurance, with final court approval scheduled for June 10, 2026 28.

FY2025: Doximity

Doximity delivered fiscal 2025 revenue of 570.4 million, up 20% year-over-year, with subscription revenue growing 21% to $543.8 million as new and expanded customer relationships drove the top line 19. Net income rose 51% to 223.2 million and adjusted EBITDA increased 36% to $313.8 million, with the adjusted EBITDA margin expanding to 55% from 48% 19 20. Operating cash flow increased 48% to 273.3 million for the full year, and cash and marketable securities stood at $915.7 million as of March 31, 2025 19 20. Doximity's registered membership exceeded two million providers, including more than 80% of U.S. physicians; strategic additions during the year included Doximity GPT, a HIPAA-compliant generative AI writing assistant, and the AMiON on-call scheduling tool 20.

FY2024: Doximity

Doximity delivered full-year revenue of USD 475.4 million in FY2024, up 13% year-over-year, driven by a $60.3 million increase in subscription revenue 12. Net income increased to USD 147.6 million, up 31% year-over-year 11, and gross margin improved to 89% from 87%, partly supported by cost reductions from the August 2023 workforce restructuring 12. Operating cash flow was USD 184.1 million for the year, with free cash flow of USD 183.9 million 119. Doximity expanded its member network to over two million registered medical professionals by March 31, 2024 and launched Doximity GPT, a HIPAA-compliant generative AI writing assistant for physicians and medical professionals 12.

FY2023: Doximity

Doximity reported full-year fiscal 2023 revenue of USD 419.1 million, up 22% year-over-year, a deceleration from 66% growth in fiscal year 2022 4. Net income was USD 112.8 million, below the prior-year level primarily due to reduced tax deduction benefits from stock option activities compared to the prior year 4. The net revenue retention rate fell to 119% as of December 31, 2022 from 171% a year earlier, reflecting slower expansion within the existing customer base 1. Operating cash flow increased 42% year-over-year to USD 179.6 million 3. Following third-quarter results, Doximity raised its fiscal year 2024 revenue guidance to exceed $500 million with an adjusted EBITDA margin target of 43% or greater 2.

Glossary

  • Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
  • Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
  • Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
  • EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
  • Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
  • EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
  • EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
  • FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
  • OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
  • Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
  • *: derived, the formula is in the hover
  • ≈: calculated, approximation
  • ~: uncertain; the value stays visible, verdicts do not use it
  • °: repaired by a targeted query against the document, or curated with documentary evidence
  • EBIT: EBIT as a fallback: the income statement carries no operating line
  • basic: basic earnings per share as a fallback when diluted is missing

Sources: quarterly reports, annual reports and investor relations documents

36 sources on Doximity since 2024; the superscript numbers in the chapters refer to these rows, older documents are in the expandable part. NadirAlpha methodology

36 documents · 2021 to 2026 · SEC EDGAR (USA)
Sources for Doximity stock: 36 original documents, 2021 to 2026. Compiled by NadirAlpha.
#Document typePublished
#110-Q quarterly report2023-02-09
#2 / #1028-K-EX99.1 earnings release2023-02-09
#3 / #1038-K-EX99.1 earnings release2023-05-16
#410-K annual report2023-05-26
#510-Q quarterly report2023-08-08
#6 / #1068-K-EX99.1 earnings release2023-08-08
#710-Q quarterly report2023-11-09
#8 / #1088-K-EX99.1 earnings release2023-11-09
#910-Q quarterly report2024-02-08
#10 / #1108-K-EX99.1 earnings release2024-02-08
#11 / #1118-K-EX99.1 earnings release2024-05-16
#1210-K annual report2024-05-23
#1310-Q quarterly report2024-08-08
#14 / #1148-K-EX99.1 earnings release2024-08-08
#1510-Q quarterly report2024-11-07
#16 / #1168-K-EX99.1 earnings release2024-11-07
#1710-Q quarterly report2025-02-06
#18 / #1188-K-EX99.1 earnings release2025-02-06
#19 / #1198-K-EX99.1 earnings release2025-05-15
#2010-K annual report2025-05-20
#2110-Q quarterly report2025-08-07
#22 / #1228-K-EX99.1 earnings release2025-08-07
#2310-Q quarterly report2025-11-06
#24 / #1248-K-EX99.1 earnings release2025-11-06
#2510-Q quarterly report2026-02-05
#26 / #1268-K-EX99.1 earnings release2026-02-05
#27 / #1278-K-EX99.1 earnings release2026-05-13
#2810-K annual report2026-05-19
#2910-Q quarterly report2026-08-06
#30 / #1308-K-EX99.1 earnings release2026-08-06
Older sources (+6)
Older sources for Doximity, 6 documents
#Document typePublished
#20110-Q quarterly report2021-08-12
#20410-K annual report2021-08-12
#20510-Q quarterly report2021-08-12
#20210-Q quarterly report2021-11-10
#20610-Q quarterly report2021-11-10
#20310-Q quarterly report2022-02-09

Doximity Stock FAQ

Is there a management forecast (guidance) for FY2027?

Yes. Management has issued targets for FY2027, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Which additional key figures does Doximity report?

As reported for Q1 FY2027 (Apr to Jun 2026): Net revenue retention rate, Workflow active prescriber growth, Registered members, Customers with at least $500,000 TTM revenue, AI Search query growth. The chapter Reported KPIs lists every value with its source.

Where can I find the official investor relations documents of Doximity?

NadirAlpha links all 36 original filings used (SEC filings) in the sources chapter: earnings release, quarterly report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.

More reports by NadirAlpha

Recently updated

Alphabet (GOOGL)US02079K3059Figures as of Updated Margin expanding · New marketPLAID (4165.T)JP3833270006Figures as of Updated Net income halved · AcquisitionBank of Innovation (4393.T)JP3778460000Figures as of Updated Revenue decelerating · Acquisition

Comparable stocks by NadirAlpha

Abbott Laboratories (ABT)US0028241000Figures as of Updated Revenue accelerating · Guidance confirmedC3.ai (AI)US12468P1049Figures as of Updated Revenue decelerating · Free cash flow turned positiveALX Oncology (ALXO)US00166B1052Figures as of Updated PartnershipBaxter International (BAX)US0718131099Figures as of Updated Net income turned positive · Guidance raisedCoty (COTY)US2220702037Figures as of Updated Margin compressing · Guidance initiatedDorman Products (DORM)US2582781009Figures as of Updated Margin compressing · Guidance cut

All reports · US Stocks (58)